Status:
COMPLETED
Signaling Pathways Targeting Colorectal Cancer in Egypt
Lead Sponsor:
Assiut University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
Brief Summary
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. In Egypt, CRC constitutes 4.2% of all cancers with median age is 50 ...
Detailed Description
The TP53-induced glycolysis and apoptosis regulator (TIGAR) is a transcriptional target of p53. TIGAR functions as a fructose-2,6-bisphosphatase, decreasing the flux through the main glycolytic pathwa...
Eligibility Criteria
Inclusion
- All Patients confirmed histopathologically to have early stages of colorectal cancer.
- Risky group patients (including those with ulcerative colitis, chron's disease, familial adenomatous polyposis).
Exclusion
- Patients with previous history of CRC treated with chemotherapy or presence of other types of cancer.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03467308
Start Date
March 1 2018
End Date
April 1 2020
Last Update
May 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University- faculty of medicine -Medical biochemistry department
Asyut, Egypt, 71111